Formulation and Evaluation of Sustained Release Metronidazole Tablet
Year: 2025
Type: article
Abstract: Metronidazole, an antibiotic commonly used to treat infections caused by anaerobic bacteria and certain protozoa, has a broad spectrum of activity. However, its frequent dosing regimen due to its short half-life often leads to poor patient compliance and fluctuations in plasma drug concentrations. The development of sustained-release formulations of metronidazole aims to improve its therapeutic effectiveness, enhance patient adherence, and minimize side effects.This study focuses on the formulation and evaluation of sustained-release (SR) tablets of metronidazole. The SR formulation was designed to release the drug gradually over an extended period, providing a controlled plasma concentration and reducing the frequency of dosing. The formulation was developed using various excipients, including hydrophilic polymers such as hydroxypropyl methylcellulose (HPMC), which are known to control the release rate of the active pharmaceutical ingredient (API).The prepared tablets were characterized for their physicochemical properties, including drug content uniformity, hardness, friability, and in vitro release behavior. The in vitro release studies demonstrated that the SR tablets exhibited a consistent release profile, maintaining therapeutic plasma concentrations over a prolonged period compared to conventional immediate-release formulations. Furthermore, stability studies confirmed that the tablets remained stable under accelerated conditions for the intended shelf life.The pharmacokinetic studies in human volunteers revealed that the sustained-release formulation resulted in a more stable plasma concentration of metronidazole, reducing peaks and troughs, thereby enhancing its therapeutic efficacy and minimizing side effects. The results suggest that sustained-release metronidazole tablets can significantly improve patient compliance and the clinical management of infections, offering a promising alternative to conventional metronidazole dosage forms.
Author: Rohan Waghmare*1, Surekha Khamkar2
Language: English
Subfield: Pharmaceutical Science
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W6930650527
FWCI:
Cites:
Cited by:
Related to: